Form 4: BioAffinity Technologies Executive Chairman Steven Girgenti Reports Share Acquisition

Steven Girgenti, Executive Chairman of bioAffinity Technologies, reports acquiring shares and holding them directly and indirectly through a trust.

Summary

• On February 16, 2024, Steven Girgenti, the Executive Chairman of bioAffinity Technologies, acquired 39,474 shares of common stock at a price of $1.52 per share.
• These shares were granted as restricted shares and will vest in full on February 16, 2027.
• Following the transaction, Mr. Girgenti directly owns 991,758 shares.
• Mr. Girgenti also indirectly owns 8,955 shares through the Cranye Girgenti Testamentary Trust, for which he serves as a co-trustee.
• He disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of share acquisition by an executive. The acquisition itself could be seen as slightly positive, but the document is purely informational.

Positives

• The acquisition of shares by the Executive Chairman could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders.

Stakeholder Impact

• Shareholders are informed about the Executive Chairman's increased stake in the company.

Key Dates

Keywords

BIAF, bioAffinity Technologies, Steven Girgenti, Executive Chairman, share acquisition, Form 4, beneficial ownership, restricted shares, Cranye Girgenti Testamentary Trust